Literature DB >> 18545998

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Martin A Sieber1, Philipp Lengsfeld, Thomas Frenzel, Sven Golfier, Heribert Schmitt-Willich, Fred Siegmund, Jakob Walter, Hanns-Joachim Weinmann, Hubertus Pietsch.   

Abstract

Recent reports suggest that nephrogenic systemic fibrosis (NSF) is associated with the administration of gadolinium (Gd)-based contrast agents (GBCAs) and in particular with the stability of the Gd-complex. The aim of this investigation was to compare GBCAs and their potential to trigger NSF. Forty-two healthy male rats received repeated intravenous injections of six different GBCAs at high doses to simulate the exposure seen in patients with severe renal dysfunction. Histopathological and immunohistochemical analysis of the skin was performed, and the concentrations of Gd, zinc and copper were measured in several tissues by inductive coupled plasma atomic emission spectroscopy. Macroscopic and histological skin changes similar to those seen in NSF patients were only observed in rats receiving Omniscan. In addition, very high concentrations of Gd were observed in the animals treated with Omniscan, and, to a lesser extent, in animals treated with OptiMARK. Significantly lower levels of Gd were found after the treatment with ionic linear agents and even less after the treatment with macrocyclic agents. The data in this investigation strongly suggest that the stability of the Gd-complex is a key factor for the development of NSF-like symptoms in this experimental setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545998     DOI: 10.1007/s00330-008-0977-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Best practices guideline: toxicologic histopathology.

Authors:  James W Crissman; Dawn G Goodman; Paul K Hildebrandt; Robert R Maronpot; Donald A Prater; Julia H Riley; William J Seaman; Daryl C Thake
Journal:  Toxicol Pathol       Date:  2004 Jan-Feb       Impact factor: 1.902

2.  Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA.

Authors:  Corinne Planchamp; Catherine M Pastor; Luc Balant; Christoph D Becker; François Terrier; Marianne Gex-Fabry
Journal:  Invest Radiol       Date:  2005-11       Impact factor: 6.016

3.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

4.  Multihance clinical pharmacology: biodistribution and MR enhancement of the liver.

Authors:  A Spinazzi; V Lorusso; G Pirovano; P Taroni; M Kirchin; A Davies
Journal:  Acad Radiol       Date:  1998-04       Impact factor: 3.173

Review 5.  Nephrogenic systemic fibrosis: an emerging threat among renal patients.

Authors:  Danielle M DeHoratius; Shawn E Cowper
Journal:  Semin Dial       Date:  2006 May-Jun       Impact factor: 3.455

6.  Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.

Authors:  Dale R Broome; Mark S Girguis; Pedro W Baron; Alfred C Cottrell; Ingrid Kjellin; Gerald A Kirk
Journal:  AJR Am J Roentgenol       Date:  2007-02       Impact factor: 3.959

7.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

Review 8.  Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.

Authors:  E S Harpur; D Worah; P A Hals; E Holtz; K Furuhama; H Nomura
Journal:  Invest Radiol       Date:  1993-03       Impact factor: 6.016

9.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.

Authors:  Tara Anne Collidge; Peter Campbell Thomson; Patrick Barry Mark; James Phillip Traynor; Alan George Jardine; Scott Thomas William Morris; Keith Simpson; Giles Hannibal Roditi
Journal:  Radiology       Date:  2007-08-17       Impact factor: 11.105

10.  Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy.

Authors:  Lisa C Edsall; Joseph C English; Mark W Teague; James W Patterson
Journal:  J Cutan Pathol       Date:  2004-03       Impact factor: 1.587

View more
  69 in total

1.  Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?

Authors:  Sameh K Morcos
Journal:  Eur Radiol       Date:  2010-09-17       Impact factor: 5.315

2.  Comparative studies of different gadolinium agents in brain tumors: differences between gadolinium chelates and their possible influence on imaging features.

Authors:  N Anzalone
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

3.  The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice.

Authors:  Thaddeus J Wadas; Christopher D Sherman; Jeffrey H Miner; James R Duncan; Carolyn J Anderson
Journal:  Magn Reson Med       Date:  2010-11       Impact factor: 4.668

4.  Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities.

Authors:  Shruti Kanakia; Jimmy Toussaint; Praveen Kukarni; Stephen Lee; Sayan Mullick Chowdhury; Slah Khan; Sandeep K Mallipattu; Kenneth R Shroyer; William Moore; Balaji Sitharaman
Journal:  Graphene Technol       Date:  2016-08-03

Review 5.  Nephrogenic systemic fibrosis: a concise review for cardiologists.

Authors:  Benjamin Y C Cheong; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2010

Review 6.  Safety issues related to intravenous contrast agent use in magnetic resonance imaging.

Authors:  Skorn Ponrartana; Michael M Moore; Sherwin S Chan; Teresa Victoria; Jonathan R Dillman; Govind B Chavhan
Journal:  Pediatr Radiol       Date:  2021-04-19

7.  Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.

Authors:  A Luana Stanescu; Dennis W Shaw; Nozomu Murata; Kiyoko Murata; Joe C Rutledge; Ezekiel Maloney; Kenneth R Maravilla
Journal:  Pediatr Radiol       Date:  2020-01-27

Review 8.  MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.

Authors:  M Essig; N Anzalone; S E Combs; À Dörfler; S-K Lee; P Picozzi; A Rovira; M Weller; M Law
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-20       Impact factor: 3.825

Review 9.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

Review 10.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.